Showing results (101-110 of 166) with videos related to

Sort By:
Pageof 17
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2021
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Medicine|April 20, 2022
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 12, 2022
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinibMargherita Rimini, Wonseok Kang, Valentina Burgio, et al.
Cancer Medicine|December 15, 2022
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Hepatology International|September 8, 2022
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumabTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Hepatology International|June 24, 2022
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Oncology|December 1, 2022
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Medicine|October 13, 2022
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Oncology|September 14, 2022
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 6, 2023
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysisTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Pageof 17